RPG LIFE SCIENCES LTD
RPGLIFE · Pharma · NSE
₹2,108
Current Market Price
Fair Value (DCF)
₹1,074
Discount to FV
-49.0%
Updated just now
YieldIQ Score
50/100
Piotroski F-Score
4/9
Economic Moat
Wide
Confidence
53%
ROE
34.5%
Debt/Equity
0.00
WACC
9.7%
Market Cap
₹3,487 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
48.1%
Return on capital employed
EV / EBITDA
24.1×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
376.6×
EBIT covers interest
Current Ratio
3.88×
Short-term liquidity
Asset Turnover
1.08×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.6%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,108.2
Bear case
Discount -260.4%
Base case
Discount -96.2%
Bull case
Discount -62.0%
Ratio Trends
RPGLIFE · last 9 annual periods
ROE
34.5%
ROCE
48.1%
Operating Margin
—
Debt / Equity
0.00×
PE
111.9×
EV / EBITDA
10.5×
Historical Financials
RPGLIFE · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹437 Cr | ₹509 Cr | ₹577 Cr | ₹653 Cr | ₹708 Cr | +12.8% |
| EBITDA | ₹89.3 Cr | ₹107 Cr | ₹135 Cr | ₹255 Cr | ₹177 Cr | +18.6% |
| EBIT | ₹73.7 Cr | ₹92.0 Cr | ₹118 Cr | — | — | +12.6% |
| PAT | ₹51.5 Cr | ₹67.6 Cr | ₹87.7 Cr | ₹183 Cr | ₹115 Cr | +22.3% |
| EPS (diluted) | ₹31.13 | ₹40.90 | ₹53.01 | — | — | +14.2% |
| CFO | ₹64.8 Cr | ₹90.8 Cr | ₹94.4 Cr | ₹77.9 Cr | ₹56.5 Cr | -3.3% |
| CapEx | ₹-23.9 Cr | ₹-32.7 Cr | ₹-69.2 Cr | ₹-36.0 Cr | ₹-65.4 Cr | — |
| FCF | ₹40.8 Cr | ₹58.1 Cr | ₹25.1 Cr | ₹41.8 Cr | ₹-8.9 Cr | — |
| Total Assets | ₹345 Cr | ₹419 Cr | ₹513 Cr | ₹658 Cr | ₹793 Cr | +23.2% |
| Total Debt | ₹0.9 Cr | ₹0.0 Cr | ₹0.0 Cr | — | ₹20.0 Cr | +114.8% |
| Shareholders' Equity | ₹256 Cr | ₹308 Cr | ₹375 Cr | ₹531 Cr | ₹605 Cr | +24.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
RPGLIFE vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 AARTIDRUGS AARTIDRUGS | — | — | Pending | 12.6% | 15.0× |
GUJTHEM GUJTHEM | — | — | Pending | 16.2% | — |
 GUFICBIO GUFICBIO | — | — | Pending | 11.6% | — |
 ORCHPHARMA ORCHPHARMA | — | — | Pending | 7.9% | — |
BLISSGVS BLISSGVS | — | — | Pending | 10.8% | 17.7× |
Click a ticker to view its fair-value analysis.
Dividend History
9 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹68.80/sh
Last payout
2025-06-27
₹24.00
Peak payout
₹24.00
Trailing yield
1.14%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. RPG LIFE SCIENCES LTD (RPGLIFE.NS) trades at 2108.20 vs a model fair value of 1074.27, a gap of -49.0%. Piotroski F-score: 4/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of RPGLIFE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for RPGLIFE →
Compare
Head-to-head with peers
Compare RPGLIFE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse RPGLIFENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.